APD-403 is under clinical development by Acacia Pharma and currently in Phase III for Chemotherapy Induced Nausea and Vomiting. According to GlobalData, Phase III drugs for Chemotherapy Induced Nausea and Vomiting have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how APD-403’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Smarter leaders trust GlobalData
APD-403 overview
APD-403 (amisulpride) is under development for the prevention of acute and delayed chemotherapy induced nausea and vomiting (CINV). The drug candidate is administered through intravenous and oral routes and formulated as tablet to prevent delayed CINV. The drug candidate is a small molecule and acts by targeting dopamine D2 and D3-receptor. APD-403 is the sister product of APD-421. It is a repurposed dug.
See Also:
Acacia Pharma overview
Acacia Pharma a subsidiary of Acacia Pharma Group PLC, is a pharmaceutical company focused on the development and commercialization of hospital nausea and vomiting products for surgical and cancer patients. Its pipeline products include barhemsys, formerly APD421 is an intravenous formulation of amisulpride, a selective dopamine antagonist used for the treatment and prophylaxis of post-operative nausea and vomiting (PONV); APD403 an intravenous injection for cancer patients to prevent acute chemotherapy-induced nausea & vomiting (CINV) and Byfavo. The company serves transforming medicine, advancing care, and pharmaceutical sectors. It also establishes licensing and distribution agreements with pharmaceutical partners outside the US. Acacia is headquartered in Cambridge, England, the UK.
For a complete picture of APD-403’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
